Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Fulcrum Therapeutics, Inc. reports that investment funds affiliated with Tang Capital beneficially own 6,663,383 shares of common stock, held indirectly. Kevin Tang and Tang Capital Management LLC are each identified as ten percent owners, with Kevin Tang having a pecuniary interest through several Tang Capital entities.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Role
10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 6,663,383 shares (Indirect, See Footnote)
Footnotes (1)
- [object Object]
Key Figures
Indirectly owned common shares: 6,663,383 shares
Reporting persons: 2
2 metrics
Indirectly owned common shares
6,663,383 shares
Indirect beneficial ownership of Fulcrum Therapeutics, Inc. common stock via Tang Capital entities
Reporting persons
2
Kevin Tang and Tang Capital Management LLC, each listed as a ten percent owner
Key Terms
beneficially owned, pecuniary interest, ten percent owner
3 terms
beneficially owned financial
"The shares are beneficially owned by Tang Capital Partners, LP ("TCP"), Tang Capital..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interest financial
"Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."
ten percent owner financial
"Kevin Tang and Tang Capital Management LLC are each identified as a ten percent owner."
FAQ
What insider stake is reported in Fulcrum Therapeutics (FULC)'s Form 3?
The Form 3 reports an indirect beneficial stake of 6,663,383 shares of Fulcrum Therapeutics common stock. These shares are held through Tang Capital-affiliated entities in which Kevin Tang has a pecuniary interest.
Who are the reporting persons on Fulcrum Therapeutics (FULC)'s Form 3?
The reporting persons are Kevin Tang and Tang Capital Management LLC, each identified as a ten percent owner. Tang Capital Management LLC serves as general partner or manager for the investment funds that hold the Fulcrum shares.
How are Kevin Tang’s Fulcrum Therapeutics (FULC) holdings structured?
The 6,663,383 shares are beneficially owned by Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. Kevin Tang controls these entities and has a pecuniary interest in their Fulcrum holdings.
Is Kevin Tang’s ownership in Fulcrum Therapeutics (FULC) direct or indirect?
Kevin Tang’s reported ownership is indirect. The shares are held by Tang Capital investment entities, with the filing classifying the position as indirect and describing his pecuniary interest through those entities.
What type of security is disclosed in the Fulcrum Therapeutics (FULC) insider filing?
The filing covers Common Stock of Fulcrum Therapeutics, Inc. All 6,663,383 shares reported are shares of common stock beneficially owned through Tang Capital-affiliated entities rather than derivative securities.